Durable Cancer Regression Off-treatment and Effective Re-induction Therapy with an Anti-PD-1 Antibody

PURPOSE: Results from the first-in-human phase I trial of the anti-programmed death-1 (PD-1) antibody BMS-936558 in patients with treatment-refractory solid tumors, including safety, tolerability, pharmacodynamics, and immunologic correlates, have been previously reported. Here, we provide long-term...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lipson, Evan J., Sharfman, William H., Drake, Charles G., Wollner, Ira, Taube, Janis M., Anders, Robert A., Xu, Haiying, Yao, Sheng, Pons, Alice, Chen, Lieping, Pardoll, Drew M., Brahmer, Julie R., Topalian, Suzanne L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3548952/
https://ncbi.nlm.nih.gov/pubmed/23169436
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-2625
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados